1	CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS
2	FOR ICU ADMISSION OF PATIENTS WITH COVID-19 USING
3	MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING
4	
5	
6	Jose L. Izquierdo <sup>1,2</sup> , Julio Ancochea <sup>3,4,5</sup> , Savana COVID-19 Research
7	Group*, and Joan B. Soriano $(0,0)$ (ORCID 0000-0001-9740-2994)
8 9	<sup>1</sup> Universidad de Alcalá, Madrid
10	<sup>2</sup> Hospital Universitario de Guadalajara, Guadalajara
11	<sup>3</sup> Hospital Universitario de La Princesa, Madrid
12	<sup>4</sup> Universidad Autónoma de Madrid, Madrid
13	<sup>o</sup> Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES),
14	Instituto de Salud Carlos III (ISCIII), Madrid; all in Spain
15 16	*Savana COVID-19 Research Group are: Japacio H. Medrano, MD: Jorge Tello:
17	Alberto Porras MD PhD: Marisa Serrano PhD: Sara Lumbreras PhD
18	Universidad Pontificia Comillas (ORCID: 0000-0002-5506-9027): Carlos Del
19	Rio-Bermudez, PhD (ORCID: 0000-0002-1036-1673); Stephanie Marchesseau,
20	PhD; Ignacio Salcedo; Andrea Martínez; Claudia Maté, MD; Sergio Collazo,
21	MD; Jesús Barea, MD; María Villamayor, MD; Antonio Urda, MD, PhD; Carolina
22	de la Pinta, MD; Imanol Zubizarreta; Yolanda González, PhD; Sebastian
23	Menke, PhD (ORCID: 0000-0002-2588-6405).
24 25	Address for correspondence
26	Dr. Joan B Soriano, MD. PhD. FERS. FCCP
27	Servicio de Neumología
28	Hospital Universitario de la Princesa, UAM
29	Diego de León 62, 28005-Madrid, Spain
30 31	<b>Fmail</b> : ibsoriano2@gmail.com
32	Cellular: +34 618867769
33	
34	Date: May 5, 2020
35	File name: BigCOVIData paper_WedRXIV.docx
37	Number of references: 36 references
38	Number of illustrations: 4 figures and 2 tables; Supplementary Materials: 1 figure and
39	1 table
40	Running Title: Big data and COVID-19
41 42	<b>CONTINCT OF INTEREST:</b> INdividual forms from all co-authors are appended <b>Keywords:</b> artificial Intelligence, big data, COVID-19, electronic health records
42 43	tachypnoea, SARS-CoV-2

### 44 ABSTRACT

45

There remain many unknowns regarding the onset and clinical course of the ongoing COVID-19 pandemic. We used a combination of classic epidemiological methods, natural language processing (NLP), and machine learning (for predictive modeling), to analyse the electronic health records (EHRs) of patients with COVID-19.

50

51 We explored the unstructured free text in the EHRs within the SESCAM Healthcare 52 Network (Castilla La-Mancha, Spain) from the entire population with available EHRs 53 (1,364,924 patients) from January 1<sup>st</sup> to March 29<sup>th</sup>, 2020. We extracted related clinical 54 information upon diagnosis, progression and outcome for all COVID-19 cases, focusing 55 in those requiring ICU admission.

56

57 A total of 10,504 patients with a clinical or PCR-confirmed diagnosis of COVID-19 were 58 identified, 52.5% males, with age of 58.2±19.7 years. Upon admission, the most common symptoms were cough, fever, and dyspnoea, but all in less than half of cases. 59 Overall, 6% of hospitalized patients required ICU admission. Using a machine-learning, 60 data-driven algorithm we identified that a combination of age, fever, and tachypnoea 61 62 was the most parsimonious predictor of ICU admission: those younger than 56 years, without tachypnoea, and temperature <39°C, (or >39°C without respiratory crackles), 63 64 were free of ICU admission. On the contrary, COVID-19 patients aged 40 to 79 years were likely to be admitted to the ICU if they had tachypnoea and delayed their visit to 65 66 the ER after being seen in primary care.

67

68 Our results show that a combination of easily obtainable clinical variables (age, fever, 69 and tachypnoea with/without respiratory crackles) predicts which COVID-19 patients 70 require ICU admission.

- 71
- 72 Abstract word count: 249 words
- 73

74 Funding: This study was sponsored by SAVANA (https://www.savanamed.com/)

75

76

#### 77 INTRODUCTION

The unprecedented, global spread of the severe acute respiratory syndrome 78 79 coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) 80 requires innovative approaches that deliver immediate, real-time results[1, 2]. To date, big data technologies have only been used to estimate SARS-CoV-2 transmission[3], 81 82 and to indirectly estimate COVID-19 cases in China by using social media[4]. However, 83 there remain many unknowns regarding the onset and temporal distribution of the 84 ongoing COVID-19 pandemic. Similarly, both the individual and population burden of 85 COVID-19 are just beginning to be unravelled. To the best of our knowledge, such 86 tools[5-7] have not been used to explore the clinical characteristics and prognostic 87 factors of COVID-19[8].

Considering the unprecedented spread and severity of the ongoing COVID-19 outbreak, focus has been set on hospital's unmet need, and in particular ICU requirements[8, 9]. Indeed, health systems have been/are near collapse and independent modelling efforts have aimed to forecast a number of epidemiological estimators, including ICU use [10-12].

Previously, our team reported that the combination of big data analytics and machine learning techniques helped to better determine quality of diagnosis and treatment of chronic obstructive pulmonary disease (COPD) via an analysis of hospital electronic health records (EHRs) using natural language processing (NLP) and validated algorithms[13, 14].

By means of The BigCOVIData study, we aimed to better determine the real-world epidemiology of COVID-19 infection in a well-defined population. Using a combination of classic epidemiological methods[15], NLP, and machine learning (for predictive modeling), we analysed the clinical information contained in the EHRs of patients with COVID-19 to advance our understanding of the disease and its associated outcomes, most notably ICU admission.

104

### 105 METHODS

106

107 The BigCOVIData study was conducted in compliance with legal and regulatory 108 requirements and followed generally accepted research practices described in the ICH 109 Guideline for Good Clinical Practice, the Helsinki Declaration in its latest edition, Good 110 Pharmacoepidemiology Practices, and applicable local regulations. This study was 111 classified as a 'non-post-authorization study' (EPA) by the Spanish Agency of 112 Medicines and Health Products (AEMPS), and it was approved by the Research Ethics Committee at the University Hospital of Guadalajara (Spain). We have followed and 113 endorsed the STrengthening the Reporting of OBservational studies in Epidemiology 114 115 (STROBE) guidance for reporting observational research[16].

### 116 Study design and data source

117 This was a multicenter, non-interventional, retrospective study using data captured in 118 the EHRs of the participating hospitals within the SESCAM Healthcare Network in 119 Castilla-La Mancha, Spain (**Figure 1**). Data captured in the EHRs was collected from 120 all available departments, including inpatient hospital, outpatient hospital, and ER, for virtually all types of provided services in each participating hospital. The study period
was January 1, 2020 – March 29, 2020.

The study database was fully anonymized in a structured format and contained no personal information from patients. Likewise, personal information was not accessed during either the application of automated and algorithmic methods (i.e., NLP) or during the conversion of unstructured data into the structured database. Importantly, given that clinical information was handled in an aggregate, anonymized, and irreversibly dissociated manner, patient consent regulations do not apply to the present study

# 129 Study sample

The study sample included all patients in the source population diagnosed with COVID-130 19. Patients were identified on the basis of clinical diagnosis (i.e., COVID-19 cases 131 determined by observed symptomatology, imaging (mostly chest X-ray) and laboratory 132 results, as captured in the unstructured, free-text information in the EHRs) and/or 133 134 microbiological test results (i.e., COVID-19 cases confirmed by RT-PCR or similar available tests). Our decision to consider both PCR- and clinically confirmed cases is 135 136 justified by the limited availability of routinely administered RT-PCR tests in the region during the study period and supported by recent discussions on the far-from-optimal 137 sensitivity of RT-PCR for COVID19 (i.e., a single negative result from a single 138 specimen cannot exclude the disease in suspected cases)[17, 18]. Indeed, recent 139 reports highlight the clinical validity and relatively high sensitivity of symptom- and 140 141 imaging-based identification of COVID-19 patients, especially in early stages of the disease[17, 19, 20]. 142

# 143 **EHRead**<sup>®</sup>

To meet the study objectives, we used EHRead<sup>®</sup>[21], a technology developed by 144 SAVANA that applies NLP, machine learning, and deep learning to analyse the 145 146 unstructured free-text information written in millions of de-identified EHRs. This 147 technology enables the extraction of information from all types of EHRs and the 148 subsequent normalization of extracted clinical entities to a unique terminology. This 149 process allows for further analysis of descriptive or predictive nature. Originally based 150 on SNOMED CT terminology, our unique body of terminology comprises more than 400,000 medical concepts, acronyms, and laboratory parameters aggregated over the 151 course of five years of free-text mining, targeting the most common diseases (e.g. 152 153 respiratory diseases, cardiovascular diseases, and diabetes, among others).

154 Using a combination of regular expression (regex) rules and machine learning models, 155 the terminology entities are detected in the unstructured text and later classified based on sections typically contained in the EHRs, hospital services, and other clinical 156 specifications. Importantly, each detected term is described in terms of negative, 157 158 speculative, or affirmative clinical statements; this is achieved by using deep learning 159 CNN classification methods that rely on word embeddings and context information (for 160 a similar methodological approach, see [22]). Limitations in a case by case detection 161 are also overcome with a similar approach to ensure that the detected concepts are 162 used within the appropriate context for the descriptive and predictive analysis.

For particular cases where extra specifications are required (i.e., to differentiate COVID cases from other mentions of the term related to fear of the disease or to potential contact), the detection output was manually reviewed in more than 5000 reports to avoid any possible ambiguity associated with free-text reporting. All NLP deep learning models used in this study were validated using the standard training/validation/testing approach; we used a 75/12/13 split ratio in the available annotated data (between 2,000 and 3,000 records, depending on the model) to ensure efficient generalization on unseen cases. For all developed models, we obtained Fscores greater than 0.89.

### 172 Data Analyses

All categorical variables (e.g., comorbidities, symptoms) are shown in frequency tables, 173 174 whereas continuous variables (e.g., age) are described via summary tables that include 175 the mean, standard deviation, median, minimum, maximum, and quartiles of each 176 variable. The number of missing data points for each variable is provided, if any. To test for possible statistically significant differences in the distribution of categorical 177 variables between study groups (i.e., male vs. female, ICU admission vs. No ICU 178 admission), we used Yates-corrected chi<sup>2</sup> tests. For continuous variables, mean 179 differences were tested using t-tests. Given our general population approach, and our 180 larger than usual sample size, we were interested in exploring sex-related differences 181 182 in COVID-19 patients, so most results are stratified by sex[23]. All statistical inferences were performed at the 5% significance level using 2-sided tests or 2-sided Cls. 183

#### 184 **Predictive model**

We developed a decision tree to classify COVID-19 patients according to their risk of 185 being admitted to the ICU. The two types of patients or classes considered in the 186 187 model were therefore "admitted to the ICU" and "not admitted to the ICU". The model 188 maps the characteristics of patients (the variables) to their class in the shape of a tree. 189 From a clinical perspective, this model contemplates all patient variables upon 190 admission, meaning that its predictive value is so from symptom debut until outcome. The tree is composed of nodes that branch to subsequent children nodes depending 191 192 on the patient's variables. The tree is built in such a way that each branch separates 193 the two classes as much as possible. This separation is measured as Shannon 194 entropy, where a node with an entropy of zero means that the classification is perfect 195 (either all or none of the patients were admitted to the ICU) and an entropy of one is the worst possible mix (50%/50%)[24]. 196

197 Model training and validation. The model was developed and tested on the available data from hospitalized patients that had either been admitted to the ICU or not; the 198 199 latter were either discharged from the hospital or died in the course of the disease. This 200 amounted to a total of 900 patients. Our algorithm was validated in a split of our COVID-19 sample, in a 70% training set and a 30% validation set. This means that the 201 202 model was trained with 630 patients (582 who did not require intensive care, vs 48 who 203 did) and validated over the remaining 270 patients. Because the two classes were 204 unbalanced (far fewer patients require ICU), we used the standard technique of 205 oversampling the lower class to guarantee a balance of accuracy and recall (in other 206 words, the tradeoff between false positives vs. false negatives). Further, we sought to 207 replicate the results from this validation in a posteriori sensitivity analysis, as per recent 208 recommendations for predictive modeling in COVID-19[25] and TRIPOD guidance[26]. 209 For this second validation, we trained the model with data from the provinces of Ciudad 210 Real and Guadalajara (38% of the study sample from Castilla La-Mancha), and used 211 an independent set with combined data set from the other three provinces, namely Toledo, Cuenca, and Albacete for validation. 212

213

### 214 **RESULTS**

From a source general population of 2,035,000 inhabitants, we used NLP and machine learning to analyse the clinical information contained in the EHRs of 1,364,924 anonymous patients (**Figure 1**). Among these, we identified a total of 10,504 patients diagnosed with COVID-19 (**Figure 2**). The flowchart of participation in the study up to hospital admission, ICU admission, or discharge is presented in **Figure 2**.

221 COVID-19 patients were 52.5% males, with a mean±SD age of 58.2±19.7 years, 222 (Table 1). Most COVID-19 patients were 50 years and older (Figure 3). Upon diagnosis, the most common symptoms reported were cough, fever and dyspnoea 223 224 (**Table 1**); notably, less than half of patients presented with these symptoms, probably 225 due to the fact that most were attended in primary care. Further, respiratory crackles, myalgia, and diarrhoea were identified in 5% or more of cases, while other respiratory 226 and non-respiratory signs and symptoms were less common. Sex-dependent 227 differences in sign and symptom frequencies upon diagnosis are shown in Table 1. Of 228 229 note, we observed subtle increases in frequency of diarrhoea, myalgia, headache, 230 chest pain, and anosmia in female COVID-19 patients, while men showed significant 231 increases in fever, dysphoea, respiratory crackles, ronchus, lymphopenia, and 232 tachypnoea (all p<0.05).

Similarly, the most frequent comorbidities were cardiovascular disease (48.2% of patients) -mainly arterial hypertension (33.6%) and heart disease (25.1%)- and diabetes (15.7%) (**Table 1**). Regarding respiratory diseases, COPD was present in 6.4%, asthma in 7.2%, OSA in 2%, and bronchiectasis in 1.2% of patients. Sexdependent differences in comorbidities upon diagnosis are also shown in **Table 1**; except for asthma, the frequency of all comorbidities was significantly higher in male than female COVID-19 patients (all p<0.05).

240 Next, we explored whether the distribution of comorbidities and sign/symptoms captured in the patients' EHRs upon diagnosis differed between those COVID-19 241 242 patients who were admitted to the ICU vs. those who were not (Table 2). Regarding 243 comorbidities, diabetes, obesity, cardiovascular disease (mainly hypertension), heart disease (mainly ischemic heart disease), and renal dysfunction were more common 244 among those patients who were admitted to the ICU (all p < 0.01). As for signs and 245 symptoms, cough, fever, dyspnoea, respiratory crackles, diarrhoea, tachypnoea, 246 247 lymphopenia, and rhonchus were more frequent among ICU patients (all p < 0.05). Interestingly, respiratory diseases were not more frequent among patients who were 248 admitted to the ICU (Table 2). 249

250 Finally, by using a machine-learning, data-driven algorithm, we identified that the 251 combination of three easily available clinical variables, namely age, temperature, and 252 respiratory frequency, was the most parsimonious predictor of ICU admission among 253 COVID-19 patients (Figure 4). For this model, age and temperature were captured as continuous variables, whereas tachypnoea (yes/no) was defined as respiratory 254 255 frequency of more than 20 breaths per minute. With accuracy, recall, and AUC values 256 of 0.68, 0.71, and 0.76, respectively, the presented model reached optimal balance in 257 terms of positive and negative predictive value for ICU admission. On the one hand, those younger than 56 years, without tachypnoea, and with temperature <39°C/102°F 258 259 (entropy = 0, n = 145) (or  $>39^{\circ}C/102^{\circ}F$  without respiratory crackles), were free of ICU admission, (entropy = 0, n = 18). On the other hand, COVID-19 patients aged 40 to 70 260 261 years were likely to be admitted in the ICU if they presented with tachypnoea and delayed their visit to the ER after being seen in primary care (entropy = 0, n = 104). As 262 263 stated in the Methods section, we performed an additional sensitivity analysis with

215

264 different data sets to further validate the results of our predictive model. The 265 independent data set of two provinces (Ciudad Real and Guadalajara, including a total of 753,408 individual patients, or 38% of the entire study sample from Castilla-La 266 267 Mancha; Figure 1 and Supplemental Table S1), was used to retrain our algorithm to identify ICU admission at onset; validation was performed in the remaining three 268 provinces. As shown in Supplemental Figure S1, the new decision tree identified the 269 270 same relevant clinical variables, that is age, tachypnea, temperature, and respiratory crackles/ronchus with similar (but not identical) thresholds in some of them. This 271 272 additional model reached values of accuracy, recall, and AUC of 0.85, 0.57, and 0.84, 273 respectively, thus providing additional proof of validity for our main findings.

274

### 275 DISCUSSION

276 Recent technological advances allow for the optimal and rapid extraction, integration, 277 and analysis of the unique and massive amount of untapped medical knowledge 278 captured in the EHRs. This possibility is particularly meaningful when the clinical 279 question at hand requires collecting data from a large number of patients in a very 280 limited amount of time, as is the case with the newly described COVID-19 pandemic.

281 By anonymously accessing the clinical information of more than 10,000 anonymous patients with COVID-19 (a number that largely surpasses samples included in recent 282 reports about the disease[27, 28]), we were able to describe their demographic and 283 clinical characteristics, their clinical journey, and the statistical relationship between the 284 most common symptoms and comorbidities on admission, and COVID-19 prognosis 285 286 (i.e., ICU admission). There were subtle differences in clinical symptoms at onset by sex, while all comorbidities (but asthma) were significantly higher in male than female 287 288 COVID-19 patients; these and other findings should be replicated in clinical series 289 elsewhere.

The variables identified in our ICU admission model (i.e., age, temperature, and tachypnoea) are clinically relevant as they are readily available and easily observable in the everyday practice with COVID-19 patients. Although tachypnea is not an exclusive manifestation of COVID-19 and can be present in patients suffering from other respiratory diseases (i.e., pneumonia), our model suggests that this sign (in combination with age and temperature) is the most reliable predictor of ICU use over other common symptoms and signs such as cough, dyspnea, or respiratory crackles.

297

In addition, given that the stability and capacity of ICUs worldwide is threatened by the rapid spread of the disease, the identification of individual factors that predict ICU admission may not only improve patient management but also optimize healthcare resource use and planning.

302

303 Further applied to other national and international healthcare networks, the tools and methodology presented here can potentially characterize and predict the prognosis of 304 305 COVID-19 in a timely and unprecedented manner. As recently pointed out[29, 30], 306 there might be value in the application of artificial intelligence to the current COVID-19 pandemic, not only to predict outbreaks[31] or read chest CT scans[32], but also to 307 disentangle COVID-19's clinical onset and natural history in nearly real-time. Indeed, 308 309 classical methods would have required months of questionnaire-based data collection 310 and questionnaire validation, along with multiple Ethics Board approvals and other 311 practical hurdles, all saved with our current approach.

In the race against COVID-19[33], where the goal is to curb the pandemic, it is imperative to leverage big data and intelligent analytics for the betterment of public health. However, it is of the utmost importance not to neglect privacy and public trust, to keep best practices, and to maintain responsible standards for data collection and data processing at a global scale[34].

318

### 319 Strengths and Limitations

To our knowledge, this is the first study using NLP and machine learning to access real-world data in such a large COVID-19 population. Indeed, our state-ot-the-art methodology allowed for the rapid analysis of the unstructured free-text narratives in the EHRs of one million patients from the general population of the region of Castilla La-Mancha (Spain).

325 Our methodology combined modules for sentence segmentation, tokenization, text 326 normalization, acronym disambiguation, negation detection, and a multi-dimensional 327 ranking scheme; the latter involved linguistic knowledge, statistical evidence, and 328 continuous vector representations of words and documents learned via shallow neural 329 networks. When applied to EHRs, NLP enables a) access to entire track records for all 330 patients in the target population, and b) the implementation of exploratory analysis to unravel associations between variables that have remained undetected with traditional 331 332 research methods. By considering all possible patients with the target disease, the information and analyses used here (i.e., RWD and free-scale statistics) remained 333 334 unbiased by the research question or the observers. Unlike classical statistical methods (e.g., logistic regression), the main advantage associated with the use of ML 335 336 in this context is that it allows for the automatic detection of meaningful relationships 337 between variables. For instance, if a given symptom (i.e., fever) is only relevant for certain patients (i.e., older than 50), techniques such as the classification trees used 338 339 here are suitable to uncover this relationship. In this context, although the total number of patients that required ICU use in the training set was somewhat low (48 patients), 340 341 the number of variables considered in the model was also very limited. In addition, the 342 inclusion of a validation stage reduces the likelihood of overfitting. Ultimately, the use of 343 classifications trees in this study (as opposed to other models such as Artificial Neural 344 Networks) is especially appropriate in the clinical context because they are easily 345 interpretable.

346 Regarding the geographical location of our participating hospital sites, it is worth 347 mentioning that with a total of 1,364,924 patients from the region of Castilla La-Mancha (SESCAM Healthcare Network), our sample is representative of the Spanish 348 population; Spain has been among the hardest hit countries by the pandemic, in terms 349 350 of both total cases and mortality rates [35, 36], and this region in particular is the third 351 most affected in the country, just behind Madrid and Catalonia. For this reason, we 352 anticipate that the clinical conclusions drawn here are relevant for clinicians worldwide. 353 Of note, ICU capacity in the region during the study period was not compromised yet, 354 which protects against possible bias in our training data (all patients requiring intensive 355 care were indeed admitted to the ICU).

The results and conclusions of the present study should be interpreted in light of the following limitations. First, we did not distinguish COVID-19 cases confirmed by laboratory results (i.e, RT-PCR) from those exclusively diagnosed through clinical observation (i.e., symptomatology, imaging and laboratory results). However, it should be noted that PCR and other rapid laboratory tests for the detection of SARS-CoV-2 were not routinely administered in Spain during the study period. In addition, this decision is supported by recent discussions on the clinical validity and relatively high sensitivity of symptom- and imaging-based identification of COVID-19 patients, especially in early stages of the disease[17, 19, 20]. Second, independent replications by different research groups in larger patient sets are needed to further support the clinical validity of our results.

Finally, future reports from the BIGCOVIData study may incorporate laboratory results and treatments, and contextualize the results presented here in a larger clinical picture[25].

We conclude that, in the largest series of COVID-19 patients attended during the first three months of the pandemic in Spain, 6% of all hospitalized patients required ICU; and that a combination of easily obtained clinical variables, namely age, fever, and tachypnoea predicts which COVID-19 patients require ICU admission.

374

Acknowledgments. We thank all the Savaners for helping accelerate health science
 with their daily work. This would have not been possible without every single team

member. We also thank SESCAM (Healthcare Network in Castilla-La Mancha, Spain)

for its participation in the study and for supporting the development of cutting-edge

379 technology in real time.

#### 380 **REFERENCES**

381 1. Centers for Disease Control and Prevention (CDC). Coronavirus (COVID-19) at CDC & P. 382 Available from https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed April 8, 383 2020 384 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, 385 Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. A Novel Coronavirus from Patients with 386 Pneumonia in China, 2019. N Engl J Med 2020: 382(8): 727-733. 387 Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, Parker M, Bonsall 3. 388 D, Fraser C. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital 389 contact tracing. Science 2020. 390 Qin L, Sun Q, Wang Y, Wu KF, Chen M, Shia BC, Wu SY. Prediction of Number of Cases 4. 391 of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index. Int J Environ Res Public 392 Health 2020: 17(7). 393 5. Topol EJ. High-performance medicine: the convergence of human and artificial 394 intelligence. Nat Med 2019: 25(1): 44-56. 395 Divita G, Carter M, Redd A, Zeng Q, Gupta K, Trautner B, Samore M, Gundlapalli A. 6. 396 Scaling-up NLP Pipelines to Process Large Corpora of Clinical Notes. Methods Inf Med 2015: 397 54(6): 548-552. 398 7. Burgner D, Jamieson SE, Blackwell JM. Genetic susceptibility to infectious diseases: big 399 is beautiful, but will bigger be even better? Lancet Infect Dis 2006: 6(10): 653-663. 400 8. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, Wang L, Zhang L, Li QH, Zhao L, He Y, 401 Gu XL, Ji XB, Li L, Jie ZJ, Li Q, Li XY, Lu HZ, Zhang WH, Song YL, Qu JM, Xu JF. Association 402 between ages and clinical characteristics and outcomes of coronavirus disease 2019. Eur Respir 403 J 2020. 404 9. Horton R. Offline: COVID-19-what countries must do now. The Lancet 2020: 405 395(10230): 1100. 406 10. Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, Cohn EL, Hswen Y, Hill SC, 407 Cobo MM, Zarebski AE, Li S, Wu C-H, Hulland E, Morgan JD, Wang L, O'Brien K, Scarpino 408 Samuel V, Brownstein JS, Pybus OG, Pigott DM, Kraemer MUG. Epidemiological data from the 409 COVID-19 outbreak, real-time case information. Scientific Data 2020: 7(1): 106. 410 11. Murray CJ. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-411 days and deaths by US state in the next 4 months. medRxiv 2020: 2020.2003.2027.20043752. 412 12. Sotgiu G GGCS, Miozzo M, Canonica GW, Virchow JC, Soriano JB. Advanced forecasting 413 of SARS-CoV-2 related deaths in Italy, Germany and Spain. Allergy 2020: In Press. 414 Izquierdo JL, Morena D, Gonzalez Y, Paredero JM, Perez B, Graziani D, Gutierrez M, 13. 415 Rodriguez JM. Clinical Management of COPD in a Real-World Setting. A Big Data Analysis. Arch 416 Bronconeumol 2020. 417 14. Sociedad Española de Neumología y Cirugía Torácica. Chart Review of Patients With 418 COPD, Using Electronic Medical Records and Artificial Intelligence (BigCOPData). Available from 419 https://clinicaltrials.gov/ct2/show/NCT04206098. Accessed April 13, 2020. 420 Koo D, Thacker SB. In snow's footsteps: Commentary on shoe-leather and applied 15. 421 epidemiology. Am J Epidemiol 2010: 172(6): 737-739. 422 STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 16. 423 guidance for reporting observational research. Available from http://strobe-424 statement.org/index.php?id=strobe-home. Accessed April 13, 2020. 425 Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H. Diagnosis of the 17. 426 Coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol 2020: 126: 108961. 427 Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different 18.

428 Types of Clinical Specimens. *JAMA* 2020.

429 19. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT 430 and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. 431 *Radiology*: 0(0): 200642. 432 20. Xu J, Wu R, Huang H, Zheng W, Ren X, Wu N, Ji B, Lv Y, Liu Y, Mi R. Computed 433 Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative 434 Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test. Clinical Infectious 435 Diseases 2020. 436 21. Hernandez Medrano ITG, J; Belda, C; Urena, A; Salcedo, I; Espinosa-Anke, L; Saggion, H. 437 Savana: Re-using Electronic Health Records with Artificial Intelligence. International Journal of 438 Interactive Multimedia and Artificial Intelligence 2017: 4(7): 8-12. 439 Yang Z, Dehmer M, Yli-Harja O, Emmert-Streib F. Combining deep learning with token 22. 440 selection for patient phenotyping from electronic health records. *Scientific Reports* 2020: 441 10(1): 1432. 442 The Lancet. The gendered dimensions of COVID-19. The Lancet 2020: 395(10231): 23. 443 1168. 444 24. Quinlan JR. Induction of decision trees. *Machine Learning* 1986: 1(1): 81-106. 445 25. Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, Haller MC, 446 Heinze G, Moons KGM, Riley RD, Schuit E, Smits LJM, Snell KIE, Steyerberg EW, Wallisch C, van 447 Smeden M. Prediction models for diagnosis and prognosis of covid-19 infection: systematic 448 review and critical appraisal. BMJ 2020: 369: m1328. 449 26. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers 450 AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for 451 Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015: 452 162(1): W1-73. 453 27. Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, 454 Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, 455 Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case 456 457 series. Lancet Infect Dis 2020. 458 28. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing 459 X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, 460 Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi 461 G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission 462 Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020: 463 382(13): 1199-1207. 464 29. McCall B. COVID-19 and artificial intelligence: protecting health-care workers and 465 curbing the spread. The Lancet Digital Health 2020: 2(4): e166-e167. 466 30. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M, 467 Li XY, Peng P, Shi HZ. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by 468 SARS-CoV-2: A Prospective Cohort Study. Eur Respir J 2020. 469 31. Ayyoubzadeh SM, Ayyoubzadeh SM, Zahedi H, Ahmadi M, S RNK. Predicting COVID-19 470 Incidence Through Analysis of Google Trends Data in Iran: Data Mining and Deep Learning Pilot 471 Study. JMIR Public Health Surveill 2020: 6(2): e18828. 472 32. Li L, Qin L, Xu Z, Yin Y, Wang X, Kong B, Bai J, Lu Y, Fang Z, Song Q, Cao K, Liu D, Wang 473 G, Xu Q, Fang X, Zhang S, Xia J, Xia J. Artificial Intelligence Distinguishes COVID-19 from 474 Community Acquired Pneumonia on Chest CT. Radiology 2020: 200905. 475 33. The race against COVID-19. Nat Nanotechnol 2020: 15(4): 239-240. 476 34. Ienca M, Vayena E. On the responsible use of digital data to tackle the COVID-19 477 pandemic. Nat Med 2020: 26(4): 463-464. 478 35. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation 479 Report -64. 2020. Available from https://www.who.int/docs/default-

- 480 source/coronaviruse/situation-reports/20200324-sitrep-64-covid-19.pdf?sfvrsn=723b221e\_2
- 481 Accessed March 24, 2020
- 482 36. Spanish Ministry of Health. Situación de COVID-19 en España. Ministerio de Sanidad
- 483 2020. Availabe from https://covid19.isciii.es. Accessed April 13, 2020.



485

487

488

### 489 Figure 1. Map of Castilla-La Mancha.

490 **Footnote**: Map of Castilla-La Mancha (red) within the Spanish (blue line) and

491 European territories. From a source general population of 2,035,000 inhabitants, we

492 collected and analyzed the clinical information in the EHRs of 1,364,924 patients within

493 the SESCAM Healthcare Network.



#### 495 Figure 2. Patient flowchart.

Footnote: Flowchart depicting the total number of inhabitants in the source population, the number (%) of patients with available EHRs analyzed, the number of patients diagnosed with COVID-19, and of those, the number of hospitalizations and ICU admissions.



# 501 Figure 3. Age and Sex Distribution of COVID-19 patients.

502 **Footnote**: Age distribution of incident cases of COVID-19 in females (left) and males

(right) in the study population for the period comprised between Jan 1, 2020 and March29, 2020.

504 29, 2020.



#### 506 Figure 4. Decision tree of relevant clinical variables for the prediction of ICU 507 admission in COVID-19 patients.

508 Footnote: The combination of three easily available clinical variables, namely age, temperature, and respiratory frequency, was the most parsimonious predictor of ICU 509 510 admission among COVID-19 patients. The number of patients, probability (p) of ICU 511 admission predicted by the model, and level of entropy (a measure indicating how 512 mixed or pure the classification is, where 0 indicates optimal separation of classes) are indicated in each box. The green pathway indicates that those patients with no 513 tachypnoea, younger than 56 years old, and with temperature less than 39°C/102°F 514 515 (OR more than 39°C/102°F without respiratory crackles), did not require ICU admission. On the contrary, the red pathway indicates that patients aged 40-79 years, 516 who presented with tachypnoea, and delayed their visit to the ER after being seen in 517 518 primary care, were likely to be admitted in the ICU. For this model, we obtained accuracy, recall, and AUC values of 0.68, 0.71, and 0.76, respectively (top right panel). 519 520 See text for further details.

521	TABLE 1. Baseline demographics and clinical data up	on diagnosis.
-----	---	---------------

	Female	Male	TOTAL	p-
Sox	11 = 4,904	11 = 5,519	n = 10,504	value
Eomalo	-		4 084(47 4)	
Male			5 510(52 5)	
	-		1(0,0)	
			1(0.0)	
Moon(SD)	57 4(20 0)	50.0(10.5)	58 2(10 7)	~0.001
Median(Min-Max)	58.0(0.0-100.0)	60.0(0.0-102.0)	50.2(19.7)	<0.001
	(44.0-73.0)	(46.0-74.0)	(45.0-73.0)	
Signs and Symptoms n(%)	(44.0-73.0)	(+0.0-7 +.0)	(43.0-73.0)	
Cough	2 /82(/0.8)	2 760(50 0)	5 2/3(/0 0)	0.8453
Eover	2,402(43.0)	2,700(50.0)	4 904(46 7)	<0.0400
	1 476(29.6)	1 818(32 0)	4,304(40.7)	<0.001
Byspheed Respiratory crackles	849(17.0)	1,010(02.0)	1 934(18 4)	<0.001
Diarrhoea	556(11.2)	543(9.8)	1,004(10.4)	0.03
Myalgia	<u>467(9.4)</u>	451(8.2)	919(8.7)	0.03
Hoadacho	462(0.3)	302(5.5)	764(7.3)	<0.0020
Bhonchus	279(5.6)	414(7.5)	693(6.6)	<0.001
Chest nain	287(5.8)	267(4.8)	554(5.3)	0.030
	106(3.0)	346(6.3)	542(5.2)	<0.003
Wheezing	190(3.9)	195(3.5)	389(3.7)	0.3567
Tachyphooa	135(2.7)	203(3.7)	338(3.7)	0.0050
Aposmio	166(2.2)	124(2.4)	200(2.0)	0.0059
Soro throat	60(1.4)	57(1.0)	127(1.2)	0.0000
	09(1.4)	37(1.0) 32(0.6)	127(1.2)	0.110
Ayeusia	33(0.7) 10(0.4)	32(0.0)	47(0.4)	0.00
Nourolaio	19(0.4)	20(0.3)	47(0.4)	0.4119
	19(0.4)	22(0.4)	41(0.4)	I 0.4071
Honotomogoly	3(0.2) 2(0.0)	6(0,1)	22(0.2)	0.4071
Comorbidities n(%) <sup>#</sup>	2(0.0)	0(0.1)	0(0.1)	0.3560
	2 252(45 2)	2 905(50 9)	5 059(49 2)	<0.001
	2,255(45.2)	2,005(50.8)	2,000(40.2)	<0.001
	01(1.9)	1,975(35.6)	3,327(33.0)	<0.001
Hoart Disease	91(1.0)	1520(27.0)	2620(25.1)	<0.001
	152(2.0)	1339(27.9)	2039(23.1) 627(6.0)	<0.001
Hoart failuro	243(4.0)	300(5.6)	552(5.3)	<0.001 0.1063
Diabotos	680(13.8)	057(17.3)	1646(15 7)	~0.001
Obosity	470(0.6)	457(8.3)	036(8.0)	<0.001 0.0185
Bonal dysfunction	271(5.4)	402(9.0)	330(0.3) 764(7.2)	0.010J
	171(3.4)	493(0.9) 323(5.0)	104(1.3)	<0.001
CRD	171(3.4)	323(3.9)	494(4.7)	<0.001
Chronic respiratory disease	404(9.7)	219(4.0)	703(0.7)	<0.001
	242(4.9)	262(4.9)	750(7.2)	<0.001
	490(10.0)	203(4.0) 540(0.0)	675(6.4)	<0.001
	120(2.5)	549(9.9)	075(0.4)	<0.001
syndrome (OSA)	69(1.4)	143(2.6)	212(2.0)	<0.001
Bronchiectasis	42(0.8)	87(1.6)	129(1.2)	<0.001
Chronic Liver Disease	36(0.7)	75(1 4)	111(1 1)	0.002
Cirrhosis	16(0.3)	35(0.6)	51(0.5)	0.0304
HIV	12(0.2)	22(0.4)	34(0.3)	0.2113

Footnote: \*p-values from Yates-corrected chi<sup>2</sup> test on percentage difference of female vs. male COVID-19 patients. All

522 523 524 525 tests were performed individually for each variable (comorbidity or sign/symptom, where applicable). For numerical values (i.e., age), t-tests of difference between means were used. <sup>#</sup>List of medical conditions according to SNOMED CT

terminology.

526

527 TABLE 2. Association between ICU admission and comorbidities/signs and symptoms upon

528 diagnosis in patients with COVID-19.

COMORBIDITIES				SIGNS AND SYMPTOMS			
Condition <sup>#</sup>	No ICU n(%)	ICU n(%)	p- value*	Sign or Symptom	No ICU n(%)	ICU n(%)	p- value*
Diabetes	1613(15.5)	33(39.8)	<0.001	Cough	5181(49.7)	62(74.7)	<0.001
Obesity	917(8.8)	19(22.9)	<0.001	Fever	4849(46.5)	55(66.3)	<0.001
Chronic respiratory disease	883(8.5)	5(6)	0.548	Dyspnoea	3246(31.1)	48(57.8)	<0.001
COPD	673(6.5)	2(2.4)	0.2029	Respiratory crackles	1904(18.3)	30(36.1)	<0.001
Asthma	750(7.2)	9(10.8)	0.2868	Myalgia	908(8.7)	11(13.3)	0.2066
OSA	211(2)	1(1.2)	0.8908	Diarrhoea	1084(10.4)	15(18.1)	0.0363
Bronchiectasis	129(1.2)	0(0)	0.6033	Dysphagia	47(0.5)	0(0)	1
Cardiovascular disease	4998(48)	60(72.3)	<0.001	Wheezing	383(3.7)	6(7.2)	0.1568
Hypertension	3487(33.5)	40(48.2)	0.0066	Tachypnoea	311(3)	27(32.5)	<0.001
Ischemic stroke	253(2.4)	1(1.2)	0.716	Chest pain	546(5.2)	8(9.6)	0.1237
Heart Disease	2604(25)	35(42.2)	<0.001	Lymphopenia	524(5)	18(21.7)	<0.001
Ischemic Heart Disease	616(5.9)	11(13.3)	0.0099	Headache	757(7.3)	7(8.4)	0.8442
Heart failure	548(5.3)	4(4.8)	1	Rhonchus	676(6.5)	17(20.5)	<0.001
Renal dysfunction	748(7.2)	16(19.3)	<0.001	Hepatomegaly	8(0.1)	0(0)	1
CKD	488(4.7)	6(7.2)	0.4059	Anosmia	297(2.9)	3(3.6)	0.9317
Chronic Liver Disease	109(1)	2(2.4)	0.502	Ageusia	65(0.6)	0(0)	0.9847
Cirrhosis	51(0.5)	0(0)	1	Neuralgia	41(0.4)	0(0)	1
Depression	699(6.7)	4(4.8)	0.6418	Sore throat	126(1.2)	1(1.2)	1
HIV	33(0.3)	1(1.2)	0.6536	Splenomegaly	21(0.2)	1(1.2)	0.4317

529 Footnote: \*p-values from Yates-corrected chi<sup>2</sup> test of difference between percentage of patients in either outcome

530 531

0 group. All tests were performed individually for each variable (comorbidity or sign/symptom, where applicable). <sup>#</sup>List of 1 medical conditions according to SNOMED CT terminology.